Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma
Background: Most data on autologous hematopoietic cell transplantation (auto-HCT) in myeloma are based on the use of innovator formulation of melphalan. Comparative bioequivalence and efficacy studies of generic melphalan are lacking. Methods: In this retrospective study, we report long-term outcome...
Main Authors: | Deepesh P. Lad, Pankaj Malhotra, Amol N. Patil, Ram V. Nampoothiri, Kripa Shanker Kasudhan, Alka Khadwal, Gaurav Prakash, Arihant Jain, Samir Malhotra, Neelam Varma, Savita Verma Attri, Subhash Varma |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387620301138 |
Similar Items
-
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
by: Morabito F, et al.
Published: (2021-07-01) -
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01) -
Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients
by: Kang Xue, et al.
Published: (2019-02-01) -
Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
by: Konstantin Byrgazov, et al.
Published: (2021-12-01) -
Atypical lichen myxedematosus: A case with remarkable response to low dose melphalan
by: Mini Gomathy, et al.
Published: (2017-01-01)